The 2025 Playbook: Industry Trends Shaping the Future of Biopharma 

[ad_1] Shots:  2025 marked a decisive inflection point for the global life sciences and biopharma industry. After several years defined by experimentation, abundant capital, and expansive innovation narratives, the industry entered a phase of disciplined execution.   Strategies were stress-tested, science was closely scrutinized, and only programs with clear biological rationale and operational readiness advanced.  Rather…

Read More

Know Your Investor: ARCH Venture Partners (December’25 Edition) 

[ad_1] Shots:  ARCH Venture Partners is a leading US-based venture capital firm recognized for backing bold science and building category-defining companies across biotechnology, life sciences, and transformational healthcare, with a strong focus on company creation  In 2024, ARCH completed 31 investments from Seed to Series A–F and beyond, including late-stage and private rounds. The firm backed innovators…

Read More

The WHO learned to love ‘anti-obesity’ jabs in 2025. I don’t fully agree, but I get it | Devi Sridhar

[ad_1] If there has been a hot topic in health in 2025, it’s definitely been GLP-1s, colloquially referred to as “anti-obesity” jabs. These medications, taken weekly as an injection into the abdomen, result in significant weight loss and, despite being developed to manage type 2 diabetes in those with metabolic disorders, have become mainstream in…

Read More

Pros, Cons, and the Ethics of Genetic Engineering

[ad_1] CRISPR has rapidly become one of the most influential breakthroughs in modern science. As a precise gene-editing tool, it allows researchers to cut, modify, or replace DNA sequences with remarkable accuracy. This capability has opened new pathways for treating inherited diseases, improving agricultural output, and advancing biological research. Yet with such power comes equally…

Read More